2. Academic Validation
  3. Thymidine phosphorylase: A potential new target for treating cardiovascular disease

Thymidine phosphorylase: A potential new target for treating cardiovascular disease

  • Trends Cardiovasc Med. 2018 Apr;28(3):157-171. doi: 10.1016/j.tcm.2017.10.003.
Wei Li 1,  Hong Yue 2
Affiliations

Affiliations

  • 1 Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall, University, Huntington, WV; Marshall Institute for Interdisciplinary Research, Marshall University, Huntington, WV. Electronic address: [email protected].
  • 2 Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall, University, Huntington, WV.
PMID: 29108898 DOI: 10.1016/j.tcm.2017.10.003
Abstract

We recently found that thymidine Phosphorylase (TYMP), also known as platelet-derived endothelial cell growth factor, plays an important role in platelet activation in vitro and thrombosis in vivo by participating in multiple signaling pathways. Platelets are a major source of TYMP. Since platelet-mediated clot formation is a key event in several fatal diseases, such as myocardial infarction, stroke and pulmonary embolism, understanding TYMP in depth may lead to uncovering novel mechanisms in the development of cardiovascular diseases. Targeting TYMP may become a novel therapeutic for cardiovascular disorders. In this review article, we summarize the discovery of TYMP and the potential molecular mechanisms of TYMP involved in the development of various diseases, especially cardiovascular diseases. We also offer insights regarding future studies exploring the role of TYMP in the development of Cardiovascular Disease as well as in therapy.

Keywords

Cancer; Platelets; Thrombosis; Thymidine phosphorylase.

Figures
Products